# PDUFA dates December 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-12

> 43 FDA catalysts are dated in December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in December 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2027 | [Rp2 primary completion](https://sec-api.dev/pdufa/rp2) | REPL | Hepatocellular Carcinoma; Biliary Tract Cancer | scheduled | "NCT05733598 (Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05733598)) |
| December 2027 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | scheduled | "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739435)) |
| December 2027 | [RASONQUE (daraxonrasib) primary completion](https://sec-api.dev/pdufa/daraxonrasib) | RVMD | NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC | scheduled | "NCT06881784 (Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Revolution Medicines, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06881784)) |
| December 2027 | [Hypersialylated immune globulin g primary completion](https://sec-api.dev/pdufa/hypersialylated-immune-globulin-g) | TAK | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | scheduled | "NCT06798012 (A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798012)) |
| December 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07660198 (Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07660198)) |
| December 2027 | [Alimatravir primary completion](https://sec-api.dev/pdufa/alimatravir) | MRK | HIV | scheduled | "NCT07850609 (A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850609)) |
| December 2027 | [Bgf mdi 320/14.4/9.6 μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT06283966 (A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06283966)) |
| December 2027 | [ALXN2220 primary completion](https://sec-api.dev/pdufa/alxn2220) | AZN | Transthyretin Amyloid Cardiomyopathy | scheduled | "NCT06183931 (Study of ALXN2220 Versus Placebo in Adults With ATTR-CM): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06183931)) |
| December 2027 | [TAK-755 primary completion](https://sec-api.dev/pdufa/tak-755) | TAK | Acute Ischemic Stroke | scheduled | "NCT07392450 (A Study of TAK-755 in Adults With Acute Ischemic Stroke): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-06 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07392450)) |
| December 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Papulopustular Rosacea | scheduled | "NCT07681271 (A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681271)) |
| December 2027 | [AZD0292 primary completion](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07088926 (A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-09 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088926)) |
| December 2027 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890909)) |
| December 2027 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Lymphoma, Large B-Cell, Diffuse | scheduled | "NCT06890884 (A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890884)) |
| December 2027 | [Imbruvica (ibrutinib) primary completion](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma | scheduled | "NCT05963074 (A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05963074)) |
| December 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Thrombocytopenia, Neonatal Alloimmune | scheduled | "NCT06533098 (A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06533098)) |
| December 2027 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06750094 (A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750094)) |
| December 2027 | [WIN378 primary completion](https://sec-api.dev/pdufa/win378) | WWB | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT07646587 (A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-17 (ESTIMATED); Lead Sponsor Windward Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646587)) |
| December 2027 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT07785843 (A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07785843)) |
| December 2027 | [Xywav primary completion](https://sec-api.dev/pdufa/xywav) | JAZZ | Narcolepsy; Idiopathic Hypersomnia | scheduled | "NCT07625280 (A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-23 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07625280)) |
| December 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07684144 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684144)) |
| December 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07684235 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684235)) |
| December 2027 | [BMS-986278 primary completion](https://sec-api.dev/pdufa/bms-986278) | BMY | Progressive Pulmonary Fibrosis | scheduled | "NCT06025578 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06025578)) |
| December 2027 | [Nucresiran primary completion](https://sec-api.dev/pdufa/nucresiran) | ALNY | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN | scheduled | "NCT07223203 (TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-27 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223203)) |
| December 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Agitation Associated With Alzheimer's Dementia | scheduled | "NCT06651567 (A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06651567)) |
| December 2027 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT07427394 (Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07427394)) |
| December 2027 | [Iiv-hd (standalone) primary completion](https://sec-api.dev/pdufa/iiv-hd-standalone) | SNY | Immunization; Healthy Volunteers; COVID-19 Immunization | scheduled | "NCT07890454 (Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890454)) |
| December 2027 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | HER2-positive Breast Cancer; Breast Cancer | scheduled | "NCT07102381 (A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-29 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102381)) |
| December 2027 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Relapsed/Refractory Small Cell Lung Cancer | scheduled | "NCT05060016 (A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05060016)) |
| December 2027 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI |  | scheduled | "NCT06369285 (A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06369285)) |
| December 2027 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma (RRMM) | scheduled | "NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06615479)) |
| December 2027 | [Nintedanib dry powder inhalation primary completion](https://sec-api.dev/pdufa/nintedanib-dry-powder-inhalation) | MNKD | Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07679893 (Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07679893)) |
| December 2027 | [Zimislecel primary completion](https://sec-api.dev/pdufa/zimislecel) | VRTX | Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia | scheduled | "NCT04786262 (A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04786262)) |
| December 2027 | [Tukysa (tucatinib) primary completion](https://sec-api.dev/pdufa/tucatinib) | PFE | Colorectal Neoplasms | scheduled | "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05253651)) |
| December 2027 | [Vatiquinone primary completion](https://sec-api.dev/pdufa/vatiquinone) | PTCT | Friedreich Ataxia | scheduled | "NCT05515536 (A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05515536)) |
| December 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Epilepsy; Seizures, Epileptic | scheduled | "NCT05518578 (Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05518578)) |
| December 2027 | [Adi-peg20 primary completion](https://sec-api.dev/pdufa/adi-peg20) | PII | Nonalcoholic Steatohepatitis (NASH) | scheduled | "NCT05842512 (Study of ADI-PEG 20 Versus Placebo in Subjects With NASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Polaris Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842512)) |
| December 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | scheduled | "NCT06051409 (A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051409)) |
| December 2027 | [KPL-387 primary completion](https://sec-api.dev/pdufa/kpl-387) | KNSA | Pericarditis; Pericarditis Acute; Recurrent Pericarditis | scheduled | "NCT07010159 (Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010159)) |
| December 2027 | [Acalabrutinib + r-chop standard of care primary completion](https://sec-api.dev/pdufa/acalabrutinib-r-chop-standard-of-care) | AZN | Mantle-cell Lymphoma | scheduled | "NCT07029737 (A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029737)) |
| December 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT07141329 (SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07141329)) |
| December 2027 | [KPL-387 primary completion](https://sec-api.dev/pdufa/kpl-387) | KNSA | Recurrent Pericarditis; Heart Diseases; Pericarditis | scheduled | "NCT07288216 (Transition to KPL-387 Monotherapy Dosing & Administration Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288216)) |
| December 2027 | [Gamunex-c primary completion](https://sec-api.dev/pdufa/gamunex-c) | GRFS | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | scheduled | "NCT07540221 (A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Grifols Therapeutics LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07540221)) |
| December 2027 | [Ramantamig primary completion](https://sec-api.dev/pdufa/ramantamig) | JNJ | Multiple Myeloma | scheduled | "NCT07589634 (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589634)) |

Other months: https://sec-api.dev/fda-calendar/2027-11 , https://sec-api.dev/fda-calendar/2028-01. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates December 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-12

```bibtex
@misc{secapidev_fda_calendar_2027_12_20261116,
  title        = {PDUFA dates December 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-12}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_12_20261116","title":"PDUFA dates December 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-12","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
